Fibrate
clofibrate
CAS: 637-07-0
Molecular Formula: C12H15ClO3
Fibrate - Names and Identifiers
Fibrate - Physico-chemical Properties
| Molecular Formula | C12H15ClO3 |
| Molar Mass | 242.7 |
| Density | 1.14g/mLat 25°C(lit.) |
| Melting Point | <25 °C |
| Boling Point | 154 °C |
| Flash Point | 113°C |
| Water Solubility | 97.08mg/L(room temperature) |
| Solubility | Several insoluble in water, soluble in boiling ethanol, easily soluble in chloroform or benzene. |
| Vapor Presure | 0.00528mmHg at 25°C |
| Appearance | White or white-like crystals or crystalline powders |
| Color | clear, colorless |
| Merck | 14,2377 |
| BRN | 1913459 |
| Storage Condition | 2-8°C |
| Refractive Index | n20/D 1.503 |
| Physical and Chemical Properties | Density 1.137 boiling point 154-156°C refractive index 1.503 |
| Use | Used for cerebral thrombosis, cerebral arteriosclerosis, sequelae of traumatic brain injury, inner ear vertigo, coronary arteriosclerosis and diseases caused by peripheral circulation |
Fibrate - Risk and Safety
| Risk Codes | R22 - Harmful if swallowed R37/38 - Irritating to respiratory system and skin. R41 - Risk of serious damage to eyes R51/53 - Toxic to aquatic organisms, may cause long-term adverse effects in the aquatic environment. R40 - Limited evidence of a carcinogenic effect |
| Safety Description | S26 - In case of contact with eyes, rinse immediately with plenty of water and seek medical advice. S36/37/39 - Wear suitable protective clothing, gloves and eye/face protection. S61 - Avoid release to the environment. Refer to special instructions / safety data sheets. S45 - In case of accident or if you feel unwell, seek medical advice immediately (show the label whenever possible.) S36/37 - Wear suitable protective clothing and gloves. |
| UN IDs | UN 3082 9/PG 3 |
| WGK Germany | 3 |
| RTECS | UE9480000 |
| HS Code | 29189900 |
| Hazard Class | 9 |
| Toxicity | LD50 in mice, rats (g/kg): 1.28, 1.65 orally (Metz) |
Fibrate - Reference
| Reference Show more | 1. Rao Yiqin, Li Xiaoxuan, Li Pengyu, etc. Establishment of an in vitro screening method for competitive agents to improve drug permeability in Cyclodextrin Inclusion complexes [J]. Chinese Journal of Pharmacy, 2019, 54(01):61-65. |
Fibrate - Reference Information
| NIST chemical information | information provided by: webbook.nist.gov (external link) |
| (IARC) carcinogen classification | 3 (Vol. Sup 7, 66) 1996 |
| EPA chemical substance information | information provided by: ofmpeb.epa.gov (external link) |
| Introduction | Clofibrate belongs to clofibrate derivative lipid-regulating drugs, which can reduce blood lipid by reducing very low density lipoprotein, however, the mechanism of its hypolipidemic effect is not fully understood, which may involve inhibiting the release of liver lipoprotein, especially very low density lipoprotein, and cholesterol synthesis, changing liver triglyceride synthesis, and strengthening the effect of lipoprotein esterase, increases the secretion of sterols and their excretion from the feces, as well as increases the clearance of triglycerides in the circulation of very low density lipoproteins. |
| indication | clinically used for atherosclerosis and its secondary diseases, such as coronary artery disease, cerebrovascular disease, peripheral vascular disease and arterial disease caused by diabetes. |
| Use | as a hypolipidemic drug, clofibrate can inhibit the synthesis of cholesterol and triglyceride and increase the excretion of sterols, reduce the content of VLDL in blood, in addition to reduce the content of plasma fibrinogen and platelet viscosity, thus, to prevent the formation of thrombosis, reduce myocardial infarction Incidence Rate, for hyperlipidemia and atherosclerosis. used for cerebral thrombosis, cerebral arteriosclerosis, sequelae of traumatic brain injury, inner ear vertigo, coronary arteriosclerosis and diseases caused by peripheral circulatory failure mainly used for the treatment of hyperlipoproteinemia hypolipidemic drugs. It can inhibit the synthesis of cholesterol and triglyceride, increase the excretion of sterols, and reduce the content of ULDL in blood. It is clinically proved that the effect of lowering triglyceride is more obvious than that of reducing cholesterol and alcohol, when the effect is strong, triglyceride can be reduced by 30-40%, cholesterol can be reduced by 15-20%, suitable for Type III, IV, V hyperesterosis, especially for Type III, and also effective for part of type II B, in addition, the product can reduce the content of plasma fibrinogen and the viscosity of platelets, thus, it is beneficial to prevent the formation of thrombus, reduce myocardial infarction by Incidence Rate, and is used for hyperesteremia and arteriosclerosis. Taking the individual patients have Nausea, Vomit, loss of appetite, abdominal distension, Diarrhea and other symptoms. In order to reduce gastrointestinal reactions, it is advisable to start with small doses and gradually increase them later, but the prescribed dose should be reached in the first month of treatment. It is better to use the method of decreasing when stopping the drug. Liver and kidney dysfunction with caution. No use in pregnant women. Toxicity: Oral LD50 mice 1.28g/kg; Rats 1.65g/kg. |
| production method | According to the raw materials used, there are two main qualified routes for this product, first, P-chlorophenol is prepared by diazotization and substitution of p-aminophenol as raw material, and then by condensation, hydrolysis, acidification to generate p-chlorophenoxyisobutyric acid, and finally esterification to obtain antoamine. The steps of this route are longer, and the raw materials used are unstable to the aminophenol, but they are more mature. Second, phenol is used as raw material, phenoxyisobutyric acid is produced by condensation, and then chlorine is passed in ethanol to conduct chlorination and esterification reaction to produce antoamine. |
| category | toxic substances |
| toxicity grade | poisoning |
| Acute toxicity | oral-rat LD50: 940 mg/kg; Oral-mouse LD50: 1220 mg/kg |
| flammability hazard characteristics | flammable; Toxic chloride smoke produced by combustion; Side effects of patients: muscle weakness, muscle cramps, fever |
| storage and transportation characteristics | ventilation and low temperature drying |
| fire extinguishing agent | dry powder, foam, sand, carbon dioxide, water mist |
| toxic substance data | information provided by: pubchem.ncbi.nlm.nih.gov (external link) |
Last Update：2024-04-09 19:05:13
Supplier List
Product Name: clofibrate Request for quotation
CAS: 637-07-0
Tel: 0086-551-65418684
Email: sales@tnjchem.com
info@tnjchem.com
Mobile: 0086 189 4982 3763
QQ: 2881500840
Wechat: 0086 189 4982 3763
WhatsApp: 0086 189 4982 3763
Product List: View Catalog
CAS: 637-07-0
Tel: 0086-551-65418684
Email: sales@tnjchem.com
info@tnjchem.com
Mobile: 0086 189 4982 3763
QQ: 2881500840
Wechat: 0086 189 4982 3763
WhatsApp: 0086 189 4982 3763
Product List: View Catalog
Product Name: clofibrate Request for quotation
CAS: 637-07-0
Tel: 0086-551-65418684
Email: sales@tnjchem.com
info@tnjchem.com
Mobile: 0086 189 4982 3763
QQ: 2881500840
Wechat: 0086 189 4982 3763
WhatsApp: 0086 189 4982 3763
Product List: View Catalog
CAS: 637-07-0
Tel: 0086-551-65418684
Email: sales@tnjchem.com
info@tnjchem.com
Mobile: 0086 189 4982 3763
QQ: 2881500840
Wechat: 0086 189 4982 3763
WhatsApp: 0086 189 4982 3763
Product List: View Catalog
View History